ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease

Nada Hamad; Ian Bilmon; Lynette Chee; Andrea Henden; Anna Johnston; Duncan Purtill; Ashish Bajel; Siok-Keen Tey; David Yeung; Theresa Cole; Clinton Lewis; Jason Butler

doi:10.1111/imj.16255

ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease

Intern Med J. 2023 Dec;53(12):2319-2329. doi: 10.1111/imj.16255. Epub 2023 Nov 28.

Authors

Nada Hamad^{1

2

3}, Ian Bilmon⁴, Lynette Chee^{5

6}, Andrea Henden⁷, Anna Johnston⁸, Duncan Purtill^{9

10}, Ashish Bajel^{5

6}, Siok-Keen Tey⁷, David Yeung^{11

12}, Theresa Cole¹³, Clinton Lewis¹⁴, Jason Butler⁷

Affiliations

¹ St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
² School of Clinical Medicine, UNSW Medicine & Health, Sydney, New South Wales, Australia.
³ School of Medicine, Sydney University of Notre Dame, Sydney, New South Wales, Australia.
⁴ Westmead Hospital, Sydney, New South Wales, Australia.
⁵ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁶ Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁷ Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁸ Royal Hobart Hospital, Hobart, Tasmania, Australia.
⁹ Fiona Stanley Hospital, Perth, Western Australia, Australia.
¹⁰ PathWest Laboratory Medicine, Perth, Western Australia, Australia.
¹¹ Royal Adelaide Hospital, Adelaide, South Australia, Australia.
¹² South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
¹³ Royal Children's Hospital, Melbourne, Victoria, Australia.
¹⁴ Auckland City Hospital, Auckland, New Zealand.

PMID: 38014511
DOI: 10.1111/imj.16255

Abstract

This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.

Keywords: GvHD; acute; chronic; graft-versus-host disease; ruxolitinib.

MeSH terms

Acute Disease
Adrenal Cortex Hormones / therapeutic use
Bronchiolitis Obliterans Syndrome*
Chronic Disease
Consensus
Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation*
Humans
Nitriles
Steroids / therapeutic use

Substances

ruxolitinib
Steroids
Nitriles
Adrenal Cortex Hormones

Grants and funding

Novartis Pharmaceuticals Australia Pty Limited